24.46
price up icon0.82%   0.225
 
loading
Schlusskurs vom Vortag:
$24.24
Offen:
$24.275
24-Stunden-Volumen:
2.10M
Relative Volume:
0.04
Marktkapitalisierung:
$138.15B
Einnahmen:
$62.46B
Nettoeinkommen (Verlust:
$7.88B
KGV:
17.73
EPS:
1.38
Netto-Cashflow:
$11.22B
1W Leistung:
+0.53%
1M Leistung:
+4.04%
6M Leistung:
-7.89%
1J Leistung:
-13.40%
1-Tages-Spanne:
Value
$24.26
$24.45
1-Wochen-Bereich:
Value
$24.07
$24.44
52-Wochen-Spanne:
Value
$20.91
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
Firmenname
Pfizer Inc
Name
Telefon
(212) 733-2323
Name
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Mitarbeiter
81,000
Name
Twitter
@Pfizer
Name
Nächster Verdiensttermin
2025-02-04
Name
Neueste SEC-Einreichungen
Name
PFE's Discussions on Twitter

Vergleichen Sie PFE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
PFE
Pfizer Inc
24.45 138.15B 62.46B 7.88B 11.22B 1.38
Drug Manufacturers - General icon
LLY
Lilly Eli Co
780.87 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.61 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.43 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.50 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
122.47 234.21B 53.22B 12.86B 14.85B 6.39

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-22 Eingeleitet Cantor Fitzgerald Neutral
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Underperform
2024-10-25 Fortgesetzt Citigroup Neutral
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-08-07 Hochstufung Daiwa Securities Neutral → Outperform
2024-03-22 Herabstufung Argus Buy → Hold
2024-02-23 Eingeleitet Guggenheim Buy
2024-01-04 Herabstufung TD Cowen Outperform → Market Perform
2023-10-20 Fortgesetzt UBS Neutral
2023-10-16 Hochstufung Jefferies Hold → Buy
2023-07-17 Bestätigt JP Morgan Neutral
2023-07-14 Eingeleitet HSBC Securities Buy
2023-06-29 Herabstufung Credit Suisse Outperform → Neutral
2023-05-11 Herabstufung Daiwa Securities Outperform → Neutral
2023-03-06 Eingeleitet Jefferies Hold
2023-02-07 Hochstufung Daiwa Securities Neutral → Outperform
2023-01-26 Herabstufung UBS Buy → Neutral
2023-01-17 Herabstufung Wells Fargo Overweight → Equal Weight
2023-01-04 Herabstufung BofA Securities Buy → Neutral
2022-12-13 Hochstufung Goldman Neutral → Buy
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-04-06 Fortgesetzt Morgan Stanley Equal-Weight
2022-01-05 Hochstufung BofA Securities Neutral → Buy
2022-01-03 Bestätigt Bernstein Mkt Perform
2021-12-20 Bestätigt Cowen Outperform
2021-12-17 Eingeleitet Goldman Neutral
2021-12-13 Hochstufung UBS Neutral → Buy
2021-12-09 Eingeleitet Wells Fargo Overweight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-07-27 Fortgesetzt Truist Buy
2021-05-06 Herabstufung Mizuho Buy → Neutral
2021-04-07 Fortgesetzt RBC Capital Mkts Sector Perform
2021-02-04 Hochstufung DZ Bank Hold → Buy
2020-12-16 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-11-19 Fortgesetzt Goldman Neutral
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-10-12 Herabstufung Atlantic Equities Overweight → Neutral
2020-09-29 Eingeleitet Berenberg Hold
2020-06-16 Eingeleitet SVB Leerink Mkt Perform
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-27 Hochstufung Standpoint Research Hold → Buy
2020-02-06 Eingeleitet Mizuho Buy
2020-01-07 Eingeleitet RBC Capital Mkts Outperform
2019-10-17 Fortgesetzt BofA/Merrill Neutral
2019-07-30 Herabstufung BofA/Merrill Buy → Neutral
2019-07-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2019-06-04 Fortgesetzt Morgan Stanley Overweight
2019-02-20 Fortgesetzt Citigroup Neutral
2019-01-31 Hochstufung Argus Hold → Buy
2019-01-31 Hochstufung Credit Suisse Neutral → Outperform
2019-01-23 Herabstufung UBS Buy → Neutral
2018-12-11 Herabstufung JP Morgan Overweight → Neutral
2018-11-01 Herabstufung BMO Capital Markets Outperform → Market Perform
Alle ansehen

Pfizer Inc Aktie (PFE) Neueste Nachrichten

pulisher
Jun 19, 2025

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707 - geneonline.com

Jun 19, 2025
pulisher
Jun 18, 2025

Transcript : Pfizer Inc.Special Call - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Is Pfizer Stock a Buy for Its Massive 7% Dividend Yield? A Trader’s Look - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 17, 2025

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global

Jun 17, 2025
pulisher
Jun 17, 2025

Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others - Fierce Pharma

Jun 17, 2025
pulisher
Jun 17, 2025

Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC

Jun 17, 2025
pulisher
Jun 17, 2025

Should Value Investors Buy Pfizer (PFE) Stock? - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC

Jun 17, 2025
pulisher
Jun 16, 2025

Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail

Jun 16, 2025
pulisher
Jun 15, 2025

Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE) - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - Yahoo Finance

Jun 15, 2025
pulisher
Jun 15, 2025

Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT - Insider Monkey

Jun 15, 2025
pulisher
Jun 15, 2025

Pfizer (PFE) Stock: Analyst Targets Suggest 15% Upside as Company Touts Strong Margins and Dividend - Daily Chhattisgarh News

Jun 15, 2025
pulisher
Jun 14, 2025

FDA Denies Pfizer's (PFE) Label Expansion for Talzenna in Prosta - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer bid to expand Talzenna label faces FDA snub (PFE:NYSE) - Seeking Alpha

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer Secures Global Licensing Rights for 3SBio’s Dual-Target Cancer Therapy Excluding China - geneonline.com

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer (PFE) Option Activity Shows Mixed Sentiment | PFE Stock N - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer’s SWOT analysis: stock outlook amid pipeline progress, cost cuts - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Pfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Young minds dive into discovery at Pfizer School of Science Mobile Experience - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility - Pfizer

Jun 13, 2025
pulisher
Jun 13, 2025

BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Pfizer (PFE) Stock Shows Strong Rebound with Over 8% Monthly Gain, Halting Longer-Term Slide - Daily Chhattisgarh News

Jun 13, 2025
pulisher
Jun 13, 2025

Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corp - The Globe and Mail

Jun 13, 2025
pulisher
Jun 12, 2025

PFIZER INC : UBS remains Neutral - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For ... - Bluefield Daily Telegraph

Jun 12, 2025
pulisher
Jun 12, 2025

Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland - CNBC

Jun 12, 2025
pulisher
Jun 12, 2025

4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts - 24/7 Wall St.

Jun 12, 2025
pulisher
Jun 12, 2025

Pfizer (PFE) Sees Mixed Options Sentiment Amidst Modest Share In - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jun 11, 2025
pulisher
Jun 11, 2025

Pfizer Scraps Bid for Depo-Provera Mass Tort Following Dismissal of Most Phila. Plaintiffs - Law.com

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Remains a Hold on Pfizer (PFE) - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Pfizer says drugmakers met with Trump admin to discuss lowering drug prices - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Request for Proposals: Pfizer Independent Research Grant Program 2025 - fundsforNGOs

Jun 11, 2025
pulisher
Jun 10, 2025

10 Best Wide Moat Stocks To Buy Now - Insider Monkey

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Globe and Mail

Jun 10, 2025
pulisher
Jun 10, 2025

Why China Biotech Is Getting a DeepSeek Moment, Too - Bloomberg.com

Jun 10, 2025
pulisher
Jun 10, 2025

Pfizer Settles With Final Defendant in Mektovi Patent Lawsuit - Bloomberg Law News

Jun 10, 2025
pulisher
Jun 10, 2025

Pfizer Stock Rallies Over 8% in a Month, but Faces Long-Term Headwinds - Daily Chhattisgarh News

Jun 10, 2025
pulisher
Jun 10, 2025

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.’s Firing of Vaccine Advisors. - Barron's

Jun 10, 2025
pulisher
Jun 10, 2025

Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Love These Ultra-High Yield Dividend Stocks - 24/7 Wall St.

Jun 10, 2025
pulisher
Jun 10, 2025

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Cantor Fitzgerald holds Pfizer stock at Neutral with $24 target By Investing.com - Investing.com India

Jun 10, 2025
pulisher
Jun 10, 2025

Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare (NYSE:PFE) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 09, 2025

No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says - Reuters

Jun 09, 2025
pulisher
Jun 09, 2025

Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves By Stocktwits - Investing.com India

Jun 09, 2025

Finanzdaten der Pfizer Inc-Aktie (PFE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$111.58
price up icon 0.97%
drug_manufacturers_general SNY
$48.21
price down icon 0.19%
$280.45
price up icon 0.68%
drug_manufacturers_general MRK
$79.06
price down icon 0.06%
drug_manufacturers_general NVS
$122.30
price up icon 1.02%
Kapitalisierung:     |  Volumen (24h):